Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.

@article{Bryant2010LinaclotideIA,
  title={Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.},
  author={Alexander P. Bryant and Robert W. Busby and Wilmin P Bartolini and Etchell A Cordero and Gerhard Hannig and Marco M. Kessler and Christine M. Pierce and Robert M. Solinga and Jenny Vittum Tobin and Shalina Mahajan-Miklos and Mitchell B. Cohen and Caroline B. Kurtz and Mark G. Currie},
  journal={Life sciences},
  year={2010},
  volume={86 19-20},
  pages={
          760-5
        }
}
AIMS Linaclotide is an orally administered 14-amino acid peptide being developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation. We determined the stability of linaclotide in the intestine, measured the oral bioavailability, and investigated whether the pharmacodynamic effects elicited in rodent models of gastrointestinal function are mechanistically linked to the activation of intestinal guanylate cyclase C (GC-C). MAIN METHODS… CONTINUE READING
Highly Cited
This paper has 66 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

67 Citations

051015'11'13'15'17'19
Citations per Year
Semantic Scholar estimates that this publication has 67 citations based on the available data.

See our FAQ for additional information.